Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes - PACE-CME

Large risk reductions with SGLT inhibitor in HFrEF with or without diabetes

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Smartphone-based AF screening in the general population
Smartphone-based AF screening in the general population
ESC 2019
Smartphone-based AF screening in the general population
Hs-troponin measured 30 min after admission to diagnose MI
Hs-troponin measured 30 min after admission to diagnose MI
ESC 2019
Hs-troponin measured 30 min after admission to diagnose MI
- Camilla Bang, MD
Sex-related differences in ACS patients
Sex-related differences in ACS patients
ESC 2019
Sex-related differences in ACS patients
- Sanne Peters, PhD
NP metabolism associated with clinical outcomes in HF
NP metabolism associated with clinical outcomes in HF
ESC 2019
NP metabolism associated with clinical outcomes in HF
- Frank Gommans, MD, PhD